Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of oxymatrine in preparation of medicine for prevention and treatment of diabetic nephropathy

A technology for oxymatrine and diabetic nephropathy, applied in drug combination, urinary system diseases, metabolic diseases, etc., can solve problems such as poor targeting and inability to repair kidneys

Active Publication Date: 2013-12-11
杨中林
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinical drugs for diabetic nephropathy are mainly hypoglycemic drugs, blood pressure lowering drugs and blood lipid lowering drugs, but these drugs are not highly targeted and cannot repair the damaged kidneys.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of oxymatrine in preparation of medicine for prevention and treatment of diabetic nephropathy
  • Application of oxymatrine in preparation of medicine for prevention and treatment of diabetic nephropathy
  • Application of oxymatrine in preparation of medicine for prevention and treatment of diabetic nephropathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1. Experimental study on the prevention and treatment of diabetic nephropathy by oxymatrine

[0030] 1. Modeling and drug administration

[0031] The animal model used is the combination of high-fat diet and STZ, and the resulting diabetic model rats have the characteristics of both type 1 and type 2 diabetes.

[0032] After 1 week of adaptive feeding, 8 rats were randomly selected as blank control group, and the group was fed with normal feed; the remaining rats were fed with high-sugar and high-fat feed (70% basal feed, 15% sucrose, 10% lard). and 5% egg yolk powder). After 4 weeks of continuous feeding, rats fed a high-sugar and high-fat diet were given a one-time intraperitoneal injection of 5 mL / kg of newly prepared STZ solution with a concentration of 6 mg / mL, and rats in the blank control group were given a one-time intraperitoneal injection of citric acid-sodium citrate buffer. Salt solution 5mL / kg. After 1 week of intraperitoneal injection, the rats ...

Embodiment 2 8

[0086] Example 2. Sample preparations of 98% oxymatrine, 50% oxymatrine and 10% oxymatrine

[0087] The preparation method of 98% oxymatrine capsules: take the 98.2% oxymatrine powder in Example 1 with a purity of 98.2%, add 1%-15% starch or other pharmaceutically acceptable carriers or conventional edible excipients (or other pharmaceutically acceptable Acceptable carrier or conventional food adjuvant: pharmaceutically acceptable carrier includes oral preparation adjuvant or parenteral administration adjuvant. The route of administration can be oral, injection, local administration, etc. According to the technical scheme of the present invention, The composition can be an oral preparation or an injection preparation, wherein the oral preparation includes capsules, soft capsules, granules, oral liquids, tablets, dropping pills, etc. The auxiliary materials used include: starch, sucrose, lactose, powdered sugar, glucose , Mannitol, Xylitol, Polyethylene Glycol, Isopropyl Alcohol,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses an application of oxymatrine in preparation of a medicine for prevention and treatment of diabetic nephropathy. The oxymatrine with different purity has remarkable hypoglycemic activity and high sugar-induced renal injury repair effect, and can lower the kidney hypertrophy degree caused by diabetes mellitus. The oxymatrine with different purity can remarkably inhibit the increase of urine protein and urinary albumin excretion caused by hyperglycemia, and can delay formation of proteinuria, thereby having the effect on treating the diabetic nephropathy. The oxymatrine with different purity can remarkably inhibit the oxidative stress increase and inflammatory reaction caused by hyperglycemia, and the therapy is one way to treat the diabetic nephropathy with the oxymatrine. In comparison with the traditional Chinese medicine positive Xiaoke pill, the oxymatrine has a more remarkable treatment effect when used for preventing and treating the diabetic nephropathy; and in comparison with the chemical drug positive metformin hydrochloride, the oxymatrine has a better treatment effect and side effects are reduced obviously.

Description

Technical field: [0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to the application of oxymatrine in the preparation of medicines for preventing and treating diabetic nephropathy. technical background: [0002] Diabetic nephropathy is one of the most important complications of diabetic patients and one of the leading causes of death in diabetic patients. According to reports, the incidence of diabetic nephropathy in diabetic patients is as high as 30%-40%. Due to the complex metabolic disorders in the body of diabetic patients, once kidney damage occurs, the speed of progress and the difficulty of treatment are much greater than those of other kidney diseases. Diabetes has become the main cause of end-stage renal disease. The proportion of diabetic nephropathy in end-stage renal disease is 42% in the United States, 25% in Japan, and 16% in China, and the proportion is increasing. At present, the clinical drugs ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P3/10A61P13/12
Inventor 杨中林
Owner 杨中林
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com